chevron_leftBack
As of 24 April 2025, Transgene S.A. has a market cap of $90.08M USD, ranking #21265 globally and #302 in France. It ranks #2122 in the Healthcare sector, and #652 in the Biotechnology industry.
Key Stats
Market Cap
$90.08MUSD
79.16M EUR
Enterprise Value
$82.94MUSD
72.89M EUR
Revenue (TTM)
$7.23MUSD
6.35M EUR
EBITDA (TTM)
-$39.12MUSD
-34.37M EUR
Net Income (TTM)
-$38.66MUSD
-33.97M EUR
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Alessandro Riva
open_in_new
Employees
144
Founded
1979
Website
transgene.fr
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 3% | -6.3% | -10% | -13% | -39% | -55% |
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
TNG
Transgene SA
ISIN: FR0005175080
Shares Out.:
Shares Outstanding:
131.934M1
Shares Float:
34.62M2
|
0.6180 EUR | |
|
0OCQ
Transgene SA
ISIN: FR0005175080
|
0.6180 EUR | |
|
TRGNF
Transgene SA
ISIN: FR0005175080
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.7000 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Transgene S.A.
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Merck & Co, Sanofi, BioInvent, and Randox. Transgene SA was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
